Claims for Patent: 10,493,054

Summary for Patent: 10,493,054

Title:	Docetaxel albumin nanoparticle pharmaceutical composition, preparation method therefor and use thereof
Abstract:	The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.
Inventor(s):	Su; Zhengxing (Sichuan, CN), Yang; Likai (Sichuan, CN), Zhao; Dong (Sichuan, CN), Zhou; Jing (Sichuan, CN), Shan; Fengying (Sichuan, CN), Wang; Lichun (Sichuan, CN), Wang; Jingyi (Sichuan, CN)
Assignee:	SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO. LTD. (Chengdu, Sichuan, CN)
Application Number:	15/548,443
Patent Claims:	1. A storage stable docetaxel albumin nanoparticle pharmaceutical composition comprising: docetaxel, albumin, and amino acid(s), wherein the weight ratio of albumin to docetaxel is from 50:1 to 1:1; wherein the weight ratio of the amino acid(s) to docetaxel is from 1:1 to 20:1; wherein the amino acid(s) is selected from the group consisting of arginine, lysine, proline, cysteine, glutamic acid and mixtures thereof; and wherein the amino acid(s) inhibits the formation of the 7-epi-docetaxel impurity of docetaxel in the pharmaceutical composition thereby forming a storage stable pharmaceutical composition. 2. The pharmaceutical composition according to claim 1, wherein the amino acid(s) is the only stabilizer in the pharmaceutical composition. 3. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition optionally comprises a protein structure unfolding agent, which includes one or more of mercaptoethanol, glutathione, and acetylcysteine, and wherein the weight ratio of albumin to the protein structure unfolding agent is from 50:1 to >0:1. 4. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a nanoparticle suspension, which comprises docetaxel in a concentration of at least 1 mg/ml, and wherein the nanoparticles therein have a particle diameter of not greater than 200 nm. 5. The pharmaceutical composition according to claim 1, wherein the albumin includes one or more of recombinant albumin and serum albumin. 6. A method for preparing the pharmaceutical composition according to claim 1, wherein the method comprises the following steps: 1) dissolving docetaxel in an organic solvent preferably selected from one or more of ethanol, tert-butyl alcohol, and acetone, to obtain an organic phase; 2) using an aqueous solution containing amino acid(s) to dissolve albumin or to dilute a solution of albumin, so as to obtain a solution of albumin and amino acid(s); 3) subjecting the solution of albumin and amino acid(s) obtained in step 2) to an incubation reaction; 4) adding the organic phase obtained in step 1) to the solution obtained after the incubation reaction in step 3) under shear, to obtain a dilute solution of docetaxel albumin nanoparticles; and 5) concentrating the solution obtained in step 4) by ultrafiltration, to obtain a docetaxel albumin nanoparticle pharmaceutical composition with enhanced stability; wherein the enhanced stability is achieved by the amino acid(s) through inhibiting the formation of the 7-epi-docetaxel impurity in the docetaxel albumin nanoparticle pharmaceutical composition; wherein the weight ratio of albumin to docetaxel is not greater than 50, i.e., is from 50:1 to >0:1, preferably is from 50:1 to 1:1, and more preferably is from 20:1 to 1:1; wherein the weight ratio of the amino acid(s) to docetaxel is no less than 0.5, i.e., is .gtoreq.0.5:1, preferably is from 0.5:1 to 80:1, more preferably is no less than 1, i.e., is .gtoreq.1:1, and preferably is from 1:1 to 20:1; and wherein the amino acid(s) preferably includes at least one of arginine, lysine, proline, cysteine, and glutamic acid, and preferably is arginine. 7. The method according to claim 6, wherein step 3) further comprises adding a protein structure unfolding agent to the solution of albumin and amino acid(s) obtained in step 2) before performing the incubation reaction; wherein the protein structure unfolding agent includes one or more of mercaptoethanol, glutathione, acetylcysteine, and dithiothreitol, and wherein the weight ratio of albumin to the protein structure unfolding agent is not greater than 100:1, i.e., is from 100:1 to >0:1, and preferably is from 50:1 to >0:1. 8. The method according to claim 6, wherein alternatively, steps 2) and 3) are performed as follows: using water for injection to dissolve albumin or to dilute a solution of albumin, so as to obtain a solution of albumin, and then adding amino acid(s) before subjecting the solution to an incubation reaction. 9. The method according to claim 6, wherein alternatively, steps 2) and 3) are performed as follows: using water for injection to dissolve albumin or to dilute a solution of albumin, so as to obtain a solution of albumin; adding amino acid(s) and a protein structure unfolding agent to the solution, and performing an incubation reaction; wherein the protein structure unfolding agent includes one or more of mercaptoethanol, glutathione, acetylcysteine, and dithiothreitol; and wherein the weight ratio of albumin to the protein structure unfolding agent is not greater than 100:1, i.e., is from 100:1 to >0:1, and preferably is from 50:1 to >0:1. 10. The method according to claim 6, wherein alternatively, steps 2) and 3) are performed as follows: using water for injection to dissolve albumin or to dilute a solution of albumin, so as to obtain a solution of albumin, and subjecting the solution of albumin to an incubation reaction; and step 5) is performed as follows: concentrating the solution by ultrafiltration before adding amino acid(s) to the concentrate, to obtain a docetaxel albumin nanoparticle pharmaceutical composition with enhanced stability. 11. The method according to claim 6, wherein alternatively, steps 2) and 3) are performed as follows: using water for injection to dissolve albumin or to dilute a solution of albumin, so as to obtain a solution of albumin, adding a protein structure unfolding agent to the solution, and performing an incubation reaction; and wherein step 5) is performed as follows: concentrating the solution by ultrafiltration before adding amino acid(s) to the concentrate, to obtain a docetaxel albumin nanoparticle pharmaceutical composition with enhanced stability; wherein the protein structure unfolding agent includes one or more of mercaptoethanol, glutathione, acetylcysteine, and dithiothreitol, and wherein the weight ratio of albumin to the protein structure unfolding agent is not greater than 100:1, i.e., is from 100:1 to >0:1, and preferably is from 50:1 to >0:1. 12. A formulation comprising the docetaxel albumin nanoparticle pharmaceutical composition according to claim 1, wherein the formulation further comprises a pharmaceutically acceptable carrier and/or auxiliary material; and wherein the formulation is an injectable solution, injectable suspension, injectable emulsion, or lyophilized powder formulation. 13. A formulation comprising the docetaxel albumin nanoparticle pharmaceutical composition prepared according to the method of claim 10, wherein the formulation further comprises a pharmaceutically acceptable carrier and/or auxiliary material; and wherein the formulation is an injectable solution, injectable suspension, injectable emulsion, or lyophilized powder formulation, and preferably is a lyophilized powder formulation. 14. A method for the treatment or prevention of an abnormal cell proliferative disease or disorder, wherein the method comprises administering the pharmaceutical composition according to claim 1 to a subject in need thereof. 15. A method for the treatment or prevention of cancer, wherein the cancer includes prostate cancer, gastric cancer, colon cancer, breast cancer, head and neck cancer, pancreatic cancer, lung cancer and ovarian cancer, wherein the method comprises administering the pharmaceutical composition according to claim 1 to a subject in need thereof. 16. A method for inhibiting the formation of the 7-epi-docetaxel impurity in a docetaxel albumin nanoparticle pharmaceutical composition, wherein the method comprises adding amino acid(s) to the pharmaceutical composition; the amino acid(s) preferably includes at least one of arginine, lysine, proline, cysteine, and glutamic acid, and more preferably the amino acid(s) is arginine. 17. The method according to claim 16, wherein the pharmaceutical composition comprises: docetaxel, albumin, and amino acid(s), wherein the weight ratio of albumin to docetaxel is not greater than 50, i.e., is from 50:1 to >0:1, preferably is from 50:1 to 1:1, and more preferably is from 20:1 to 1:1; wherein the weight ratio of the amino acid(s) to docetaxel is no less than 0.5, i.e., is .gtoreq.0.5:1, preferably is from 0.5:1 to 80:1, more preferably is no less than 1, i.e., is .gtoreq.1:1, and preferably is from 1:1 to 20:1; and wherein the amino acid(s) includes at least one of arginine, lysine, proline, cysteine, and glutamic acid, and preferably is arginine. 18. A method for improving the stability of a docetaxel albumin nanoparticle pharmaceutical composition, wherein the method comprises adding amino acid(s) to the docetaxel albumin nanoparticle pharmaceutical composition, so as to inhibit the formation of the 7-epi-docetaxel impurity therein, thereby improving the stability; the amino acid(s) preferably includes at least one of arginine, lysine, proline, cysteine, and glutamic acid, and more preferably the amino acid(s) is arginine. 19. The method according to claim 18, wherein the pharmaceutical composition comprises: docetaxel, albumin, and amino acid(s), wherein the weight ratio of albumin to docetaxel is not greater than 50, i.e., is from 50:1 to >0:1, preferably is from 50:1 to 1:1, and more preferably is from 20:1 to 1:1; wherein the weight ratio of the amino acid(s) to docetaxel is no less than 0.5, i.e., is .gtoreq.0.5:1, preferably is from 0.5:1 to 80:1, more preferably is no less than 1, i.e., is .gtoreq.1:1, and preferably is from 1:1 to 20:1; and wherein the amino acid(s) includes at least one of arginine, lysine, proline, cysteine, and glutamic acid, and preferably is arginine. 20. The pharmaceutical composition according to claim 1, wherein the weight ratio of albumin to docetaxel is from 20:1 to 1:1. 21. The pharmaceutical composition according to claim 1, wherein the amino acid is arginine. 22. The pharmaceutical composition according to claim 1, wherein the albumin is human serum albumin.

Details for Patent 10,493,054

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2035-04-03
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2035-04-03
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2035-04-03
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2035-04-03